BridgeBio Oncology Therapeutics, Inc.·4

Jul 6, 6:00 PM ET

Ben Yong 4

4 · BridgeBio Oncology Therapeutics, Inc. · Filed Jul 6, 2026

Research Summary

AI-generated summary of this filing

Updated

BridgeBio Oncology (BBOT) CMO Ben Yong Withholds 1,047 Shares for Taxes

What Happened

  • Ben Yong, Chief Medical & Development Officer at BridgeBio Oncology (BBOT), had 1,047 shares of common stock withheld by the company to satisfy tax withholding obligations tied to the vesting of restricted stock units. The shares were withheld at $7.80 per share for a total value of $8,167. This was a tax-withholding disposition (transaction code F), not an open-market sale or purchase.

Key Details

  • Transaction date: 2026-07-01
  • Price per share: $7.80; Shares withheld/disposed: 1,047; Total value: $8,167
  • Shares owned after transaction: Not reported in the provided filing excerpt
  • Footnote: F1 — withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations upon RSU vesting
  • Filing: Form 4 filed 2026-07-06 (appears to be filed after the typical 2-business-day Form 4 deadline for a 2026-07-01 transaction)

Context

  • This was a routine tax-withholding action on vested RSUs (a cashless/withholding settlement), which reduces the insider's beneficially owned shares but does not reflect an open-market sale or a directional bet on the stock. Such withholdings are common and generally not interpreted as a signal of management views on the company's stock price.

Insider Transaction Report

Form 4
Period: 2026-07-01
Ben Yong
Chief Med & Dev Officer
Transactions
  • Tax Payment

    Common Stock

    [F1]
    2026-07-01$7.80/sh1,047$8,16744,576 total
Footnotes (1)
  • [F1]Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Signature
/s/ Aaron Chan, Attorney-in-Fact|2026-07-06

Documents

1 file
  • 4
    ownership.xmlPrimary

    4